Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mazdutide in Adult Participants With Obesity or Overweight
NCT06124807Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2023
- Primary completion
- Jan 2025
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of mazdutide in obesity, Overweight, sponsored by Eli Lilly and Company. Started Nov 2023; status: completed.
02
Drugs
mazdutide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06124807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06124807.